AKT1 and Familial prostate cancer: Collectively, these results robustly support the synergistic anti-tumoral effects of YJ1206 and AKT inhibitors, both in vitro and in vivo, underscoring their potential as a combined therapeutic strategy for advanced prostate cancer management.